Cancer Genetics Inc (NASDAQ: CGIX) announced some incredibly positive news with regard to the combination trial surrounding immuno-oncology agents. The company announced that it has closed its 25th contract surrounding the topic. Here’s what we saw from the PR…
CGIX Announces 25th Contract Win Surrounding Immuno-Oncology Agents
As mentioned above, Cancer Genetics released some big news this morning. The company announced that it has officially closed its 25th contract that supports a drug combination trial for immuno-oncology agents. The combination trials on the center stage are with leading pharmaceutical or biotechnology companies that are focused on providing biomarker based testing, companion diagnostic services or new test development for patient measurement and monitoring where an immuno-oncology drug is being used with another oncology therapy.
CGIX informed investors that the majority of the trials surround testing for multiple types of markers, including immune-markers like PD-1, PD-L1, and CTLA-4 as well as other targeted genomic markers. The goal is ultimately to further understand the potential for patient response and to monitor therapy effectiveness. In a statement, Panna Sharma, President and CEO at CGIX, had the following to offer…
“Achieving the goal of closing 25 leading-edge I-O combination clinical trial contracts is a major milestone for our Company and a testament to the depth and quality of our portfolio and the capabilities of our team members… Combination approaches in oncology therapy not only present a potentially dramatic advancement for cancer patient care, but also introduce new complexities in diagnostic testing, measurement, monitoring, safety, and data analysis in the clinical trial setting. With nearly half – 25 of the over 50 I-O clinical trials that we support being combination trials measuring multiple biomarkers and pathways, we are well positioned to partner with leading global pharmaceutical companies in bringing innovative cancer treatments to patients.
Combination oncology trials now demand measuring and monitoring beyond genomics, and integrated data from proteomics, immunophenotyping and cellular interactions. We believe as the range and complexity of combination therapies increase, biotech and pharma companies will have the need to partner with innovative companies that can combine innovative new technologies as part of study design and early development, and also deliver industrial-scale, clinical ready tests for patient monitoring and diagnostic use once the therapies are approved. CGI has been uniquely poised to provide this integrated, bench to bedside capability; one that is exceptional in the landscape of oncology providers.”
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on CGIX. In particular, we’re interested in following the story surrounding the ongoing success of the company’s biomarker testing. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!